AHR inhibition promoted apoptotic cell death because CH-22311 showed an additive effect with ABT-199 in CLL (cell viability from 56.6% ± 2.1% to 48.8% ± 3.0%) (Figure 5B) as deduced from the main effects obtained for the three treatments (MD = 3.80, [95% CI = 0.88; 6.73], p = 0.043; MD = -4.81, [95% CI = -7.00; -2.62], p = 0.003; MD = -16.63, [95% CI = -26.79; -6.46], p = 0.019 for Kyn, Ch-223291 and ABT-199 treatments, respectively). Here, AHR is linked to B-cell chronic lymphocytic leukemia.